section name header

Pronunciation

de-fe-RA-si-rox

Classifications

Therapeutic Classification: antidotes

Pharmacologic Classification: chelating agents

Indications

REMS


Action

  • Selectively chelates iron and eliminates it in feces.
Therapeutic effects:
  • Decreased iron with decreased sequelae of iron excess (hemosiderosis).

Pharmacokinetics

Absorption: Well absorbed (70%) following oral administration, absorption is less in children.

Distribution: Unknown.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized by the liver, followed by enterohepatic recycling. 84% excreted in feces (deferasirox and metabolites); minimal renal excretion.

Half-Life: 8–16 hr.

Time/Action Profile

(blood level)

ROUTEONSETPEAKDURATION
POunknown1.5–4 hr24 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Chronic Iron Overload Due to Blood Transfusions

Hepatic Impairment

Renal Impairment

Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndromes

Hepatic Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Exjade, Jadenu

Code

NDC Code